Mink therapeutics to participate in evercore isi healthconx conference

New york, nov. 17, 2022 (globe newswire) -- mink therapeutics, inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, announced that dr. jennifer buell, president and ceo of mink, will participate in a fireside chat at the 5th annual evercore isi healthconx conference on thursday december 1st, at 4:45 pm et.
INKT Ratings Summary
INKT Quant Ranking